MS and Demyelinating Disorders

The findings indicate that the use of a MS severity score (Ped-MSSS) model may provide an alternative to EDSS scoring, which has been shown to be lower in pediatric disease, in clinical assessment of disease severity and disability accrual.

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the benefit that physicians and patients can be provided by highly selective S1P modulators in MS treatment.

Join NeurologyLive and the Women Neurologist Group on Twitter to discuss the importance of mental health and wellness in neurologic disorders.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 24, 2020.

Data demonstrate a long-term, positive effect of the drug on cognitive function in patients with multiple sclerosis.

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic spoke to the development of the sphingosine-1-phosphate modulator class in MS treatment.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 17, 2020.

Previous exclusions limiting use of the drug in spasticity caused by cerebral palsy have been lifted.

The clinical research director at the UCSF Multiple Sclerosis Center discussed potential future assessments of inebilizumab (Uplizna; Viela Bio) and the agents still in development for NMOSD.

Low-risk, digital video game interventions could represent a clinically valuable approach to improving processing speed in adults with multiple sclerosis.

In part 2 of this interview, Daniel Ontaneda, MD, PhD, the co-principal investigator of the CAVS-MS study, describes the long-term goals of the study and how the central vein sign will be incorporated into standard diagnostic criteria for multiple sclerosis.

Treatment with natalizumab helps both confirmed disability and functional system, suggesting it may be considered when evaluating treatment options for those with relapsing-remitting multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 10, 2020.

Despite the ongoing public health emergency, many of the telehealth policies established by the CARES Act waiver are expiring.

New data suggest that peripapillary retinal nerve fiber layer thinning may be an independent and novel risk factor for conversion to multiple sclerosis in those with RIS.

Findings of the study provide a cautionary note in relation to cannabis use in people with MS, at least with respect to depression.

One of the first case-series studies that analyzed children with COVID-19 suggest that SARS-CoV-2 should be considered for differential diagnosis in children presenting with new neurologic symptoms and splenium signal changes on MRI.

In part 1 of this interview, Daniel Ontaneda, MD, PhD, the co-principal of the CAVS-MS study, outlines the reasons for why the central vein sign can lower rates of misdiagnosing multiple sclerosis.

A look at the questions you should be asking during the decision-making process of picking a telehealth vendor.

Neurology News Network for the week ending July 4, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 3, 2020.

Kottil Rammohan, MD, director of the MS Division and Multiple Sclerosis Center of Excellence at the University of Miami, discussed the EMD Serono agent’s history and advantages for the patient community.

Notably, the cohort assessment did not identify a link between exposure to disease-modifying therapies and COVID-19 severity.

An in-depth look into the expanding landscape of multiple sclerosis treatments that target bruton tyrosine kinase.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 26, 2020.

Worsened clinical outcomes for patients with MS due to an increase in comorbidities could provoke the need of greater management of them in the clinical care setting.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Bryan Davis, PsyD, MS.

The neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis and co-principal investigator of the CAVS-MS study details the specific reasons for examining central vein sign as a biomarker.

The clinical research director at the UCSF Multiple Sclerosis Center discussed the efficacy of inebilizumab (Uplizna; Viela Bio) and biomarker data observed in the N-Momentum trial in NMOSD.

The clinical research director at the UCSF Multiple Sclerosis Center shared his perspective on the recent FDA approval of inebilizumab (Uplizna; Viela Bio) for NMOSD.